Omeros
About OmerosPipelineInvestorsNews


Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.93
Change (%) Stock is Up 0.03 (0.28%)
Volume205,802
Data as of 07/22/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
07/07/16Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Jul. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor F... 
 Printer Friendly Version
06/29/16Omeros Corporation Announces Completion of Patient Enrollment in Pediatric Trial of OMIDRIA®
-- Successful Completion Expected to Lead to Additional Market Exclusivity -- SEATTLE--(BUSINESS WIRE)--Jun. 29, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that it has com... 
 Printer Friendly Version
05/17/16Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
SEATTLE--(BUSINESS WIRE)--May 17, 2016-- Omeros Corporation (NASDAQ: OMER) (the “Company”) today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC (“Oxford”) and East West Bank (“East West”) to provide the Company with an additional $20 million in unrestricted cash by funding the remaining tranches of the facility. Omeros will issue warrants to the lenders, exercisable for seven years for up to 100,60... 
 Printer Friendly Version
05/10/16Omeros Corporation Reports First Quarter 2016 Financial Results
-- Conference Call Today at 9:00 a.m. ET -- SEATTLE--(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as fina... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2015 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.